Update on the Thromboembolic Events After Vaccination Against COVID 19
Preprint
- 8 July 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
The association between COVID-19 vaccination and thromboembolic events has gar-nered significant research attention, particularly with the advent of vaccines based on adenoviral vectors, including AstraZeneca's and Johnson & Johnson's. This review un-derscores the uncommon occurrence of blood clotting events, including venous throm-boembolism (VTE), arterial thromboembolism (ATE), and vaccine-induced thrombotic thrombocytopenia (VITT), following COVID-19 vaccination. Although these complica-tions are extremely rare compared to the heightened risk of thrombosis from COVID-19 infection, elements like age, biological sex, type of vaccine and underlying health conditions may contribute to their development. Current guidelines emphasize early detection, individualized risk assessment, and the use of anticoagulation therapy to mitigate risks. Despite these rare events, the overwhelming evidence supports the con-tinued use of COVID-19 vaccines, given their proven efficacy in reducing severe illness and mortality. Ongoing research is essential to further refine preventive and therapeu-tic strategies, particularly for at-risk populations.Keywords
All Related Versions
This publication has 28 references indexed in Scilit:
- Risk benefit analysis to evaluate risk of thromboembolic events after mRNA COVID-19 vaccination and COVID-19npj Vaccines, 2024
- Thrombocytopenia and venous thromboembolic events after BNT162b2, CoronaVac, ChAdOx1 vaccines and SARS-CoV-2 infection: a self-controlled case series studyScientific Reports, 2023
- Activation of coagulation and proinflammatory pathways in thrombosis with thrombocytopenia syndrome and following COVID-19 vaccinationNature Communications, 2023
- Venous thromboembolism after COVID‐19 vaccination in patients with thrombophiliaAmerican Journal of Hematology, 2023
- Thromboembolic events following mRNA vaccines for COVID 19: a case seriesJournal of Thrombosis and Thrombolysis, 2022
- Analysis of COVID-19 Vaccine Type and Adverse Effects Following VaccinationJAMA Network Open, 2021
- Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in EnglandThe Lancet Regional Health - Europe, 2021
- First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in ScotlandNature Medicine, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Four different study designs to evaluate vaccine safety were equally validated with contrasting limitationsJournal of Clinical Epidemiology, 2006